secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tango Therapeutics, Inc. (TNGX)
CIK:        0001819133
Form:       8-K
Filed at:   2026-05-08T23:59:59+00:00
Accession:  0001193125-26-213491
Event type: leadership
Sentiment:  negative
Materiality: 0.80
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Tango Therapeutics CFO Daniella Beckman Separates; Severance Includes 12-Month Pay, Equity Acceleration
--------------------------------------------------------------------------------

- CFO Daniella Beckman ceased serving as principal financial officer effective April 15, 2026.
- Separation agreement provides 12 months severance at current base salary paid over 12 months.
- Company accelerates vesting of equity awards that would have vested in 24 months following May 1, 2026.
- Vested stock options exercise period extended through August 31, 2026.
- Beckman executed a general release in favor of the Company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819133/000119312526213491/0001193125-26-213491-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819133/000119312526213491/d102174d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-213491

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer